Stroke treatment developer Silk Road Medical (NSDQ:SILK) announced that it appointed a new executive VP of R&D and COO.
William Whealon joined as executive VP of research & development, effective immediately, while current CFO Lucas Buchanan will also operate as Silk Road’s COO, effective Oct. 1.
Whealon has over two decades of experience in the industry, having previously served as VP of R&D for the peripheral vascular business at Medtronic.
“We are excited to welcome Bill to Silk Road Medical as we further strengthen our leadership team,” Silk Road Medical president & CEO Erica Rogers said in a news release. “His proven track record for building and leading effective and innovative R&D groups and his passion for identifying solutions to solve unmet clinical needs will be instrumental in our continued efforts to achieve durable growth.”
Buchanan’s expanded role within the Sunnyvale, Calif.-based company includes added responsibility and leadership over key administrative functions and operations, including strategic initiatives, manufacturing and supply chain management.
“Lucas’ deep knowledge of our business and strong leadership skills make him the ideal COO for Silk Road Medical as we continue to focus on operational excellence while we scale our business and pursue several strategic initiatives,” Rogers said.